Impact BioMedical announces acquisition of Celios in $1.15M equity transaction

Impact BioMedical (IBO) announced the acquisition of Celios in a strategic, all equity transaction valued at approximately $1.15M. This acquisition aligns with Impact Biomedical’s focused roll-up strategy, expanding its portfolio with solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness. The company said, “Celios brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other countries with exclusivity through 2043. It delivers “virtually clean room” air quality through novel U.S. manufactured filter technology, which is highly effective, yet portable with an easy-to-use design. With the acquisition of Celios, Impact Biomedical takes a substantial step forward in its mission to deliver best-in-class healthcare and wellness solutions. The addition of Celios technology complements Impact Biomedical’s existing suite of innovations, reinforcing its ambition in human health and wellness.”